INTRODUCTION
============

Retroelements (REs) are known to comprise a significant portion of the human genome and might have a serious impact on genome functioning and evolution ([@b1],[@b2]). Of special interest for human genome studies are recently integrated and polymorphic REs.

Polymorphic REs offer considerable advantages over other types of polymorphisms. In particular, they are stable, and although it can be assumed that preexisting REs might be excised from the genome, no experimental evidence is presently known in favor of this assumption. Therefore, the presence of an RE represents identity by descent, whereas the ancestral state of the RE insertion polymorphism is known to be the absence of the RE. Thus, identification of young, recently integrated and polymorphic REs is of considerable interest for deeper understanding of primate genome evolution and relationships of various human populations, as well as for the development of new powerful tools for gene mapping.

Several groups of authors described quite a number of polymorphic and human-specific Alu, L1 and HERV-K integrations ([@b3]--[@b11]). However, no comprehensive experimental genome-wide search for polymorphic RE insertions was done so far, though bioinformatic screening of genomic databases for Alu and L1 was performed ([@b4],[@b6],[@b10],[@b12],[@b13]). A rationale for the authors\' approach was that small subsets of both Alu and L1 families amplified within the genome during recent evolutionary time (4--5 Mya) may be not fixed and may therefore display considerable polymorphism in human population. Indeed, Alu retroposition activity in human was increased some time after the divergence of the human and chimpanzee lineages, mostly due to the two most recently formed human Alu subfamilies, Alu Ya5 and Alu Yb8. The latest estimates of these subfamilies\' ages assign their amplification to a period between 2.5 and 3.5 Mya ([@b4],[@b6],[@b14]). Therefore, a computer search for recently integrated REs in the human genomic DNA sequence databases could provide candidate polymorphic retroelement integrations. This technique was applied to the identification of recently integrated Alu family members ([@b4]). As a result, 2640 and 1852 representatives of the youngest Ya5 and Yb8 groups of Alu, respectively, were identified in the human genome draft sequence. An experimental analysis of 475 of these elements revealed that although over 99% of them were restricted to the human genome, only 106 investigated Alu inserts were polymorphic in the genomes of various human populations. Similar analysis was also performed for 262 representatives of the evolutionarily young L1Hs Ta family and authors found that 115 of them were polymorphic in humans ([@b9],[@b10]): 29% and 69% of the loci that contained inserts of Ta-0 and the evolutionarily youngest Ta-1 subfamilies, respectively, were found to be polymorphic. Although RE polymorphisms are widely used for studies of human genome variability, most recently published data demonstrate that many polymorphic RE integrations are lacking from the available human genome databases ([@b15],[@b16]). Apparently, the computer searches should be accompanied by experimental checking of which of the REs identified are indeed polymorphic. In addition, many polymorphic insertions can be absent from the available human genome sequence since not only it contains gaps but it also represents only a few haplotypes taken for sequencing just by chance. Moreover, the computer search is impossible for non-sequenced genomes, in particular those of primates other than human. Unfortunately, known experimental techniques did not permit to make genome-wide analyses, although some approaches were successfully applied to detecting polymorphic retroelements ([@b15]--[@b18]).

In this report, we describe a general approach to experimental identification of polymorphic REs in the human genome without any preliminary knowledge of the genome sequences. Using this approach, we identified 41 new polymorphic Alu insertions, 18 of which were not found in the published versions of the human genome sequence, therefore being undetectable by computer search.

MATERIALS AND METHODS
=====================

DNA samples
-----------

Human DNA samples were isolated from peripheral blood lymphocytes by standard phenol/chloroform extraction and ethanol precipitation. DNA sampling from East European and Asian populations has been described elsewhere ([@b19]). The samples kindly provided by Dr E. Khusnutdinova (Institute of Biochemistry and Genetics, Ufa Research Center, Russian Academy of Sciences, Ufa, 450054 Bashkortostan, Russia) represented DNAs of 11 individuals of various ethnic origin including Chuvash, Tabasaran, Tatar, Mari, Belorussian, Nogay, Lezgin, Uzbek, Kazakh and Russian. A mixture of their DNAs was used as tracer DNA, whereas driver DNA was prepared from an Andi (Northeast branch of the North Caucasian family) male individual DNA sample.

Three genomic DNA samples isolated from placentas were used for optimization of PCR conditions.

Preparation of driver DNA
-------------------------

Andi genomic DNA (500 ng) was digested with 20 U of RsaI endonuclease (Fermentas) in 50 μl of 1× restriction buffer Y+Tango (Fermentas) at 37°C for 2 h. The digested DNA was then purified by phenol/chloroform extraction, ethanol precipitated, dissolved in 10 μl of sterile water and ligated to an excess of the adapter (15 μM) at 16°C overnight using T4 DNA ligase (Promega). To form the adapter, 150 μM A1A2 and a12 oligonucleotides ([Table 1](#tbl1){ref-type="table"}) were annealed in TM (10 mM Tris--HCl, pH 7.8, 10 mM MgCl~2~) buffer. The ligation was terminated by incubation at 65°C for 15 min. The ligates were then separated from free adapter molecules by passing through a QIAquick PCR Purification Kit (Qiagen). A fraction of Alu Ya5 and Ya8 5′ flanking sequences was amplified using the selective PCR suppression technique ([@b8],[@b20]). A1 and T1 primers ([Table 1](#tbl1){ref-type="table"}) were used in the first round of PCR. T1 primer corresponds to a fragment of the Alu sequence containing three mutations characteristic of the Alu Y subfamily, as well as two mutations distinguishing Alu Ya branch. The PCR mixture contained 10 ng of the ligate in 25 μl of 1× PCR Buffer for Advantage 2 (BD Biosciences, Clontech) containing 200 μM each of dNTPs, 0.4 μM each of primers and 0.5 μl of 50× Advantage 2 polymerase mix (BD Biosciences, Clontech). The PCR was carried out in a thermal cycler (OmniGene Hybaid) as follows: 72°C for 4 min (to extend 3′ ends of the DNA duplexes) and 23 cycles at 95°C for 25 s, 65°C for 25 s, 72°C for 80 s. The PCR products were 1000-fold diluted and re-amplified with A2 and T2 primers ([Table 1](#tbl1){ref-type="table"}) in the second PCR round (16 cycles at 94°C for 20 s, 68°C for 20 s, 72°C for 90 s). T2 primer was designed against the utmost 5′ end of Alu repeats. The PCR products obtained were purified by phenol/chloroform extraction, ethanol precipitated and dissolved in 100 μl of sterile water.

To remove A2-originated termini (residual adapter fragments), 3.75 μg of the purified PCR product was digested with 20 U of RsaI endonuclease (Fermentas) in 200 μl of 1× restriction buffer Y+Tango (Fermentas) at 37°C for 2 h. This last stage is crucial for avoiding cross-hybridization.

Preparation of tracer DNA
-------------------------

Chuvash, Tabasaran, Tatar, Mari, Belorussian, Nogay, Lezgin, Uzbek, Kazakh and Russian human genomic DNAs (100 ng each) were mixed and digested with 40 U of RsaI endonuclease (Fermentas) in 100 μl of 1× restriction buffer Y+Tango (Fermentas) at 37°C for 2 h. The digested DNA was then purified by phenol/chloroform extraction, ethanol precipitated, dissolved in 10 μl of sterile water, ligated to an excess of A1A2/a12 adapter, and two-round PCR amplified as described for driver DNA preparation. Prior to the PCR reaction, 60 pmol of oligonucleotide T2 was 5′ phosphorylated in 10 μl of 1× PNK Buffer A (Fermentas), containing 1 mM ATP and 10 U of T4 Polynucleotide Kinase (Fermentas). The PCR product was then purified by phenol/chloroform extraction, ethanol precipitated and dissolved in 100 μl of sterile water.

The purified PCR product (900 ng) was digested with RsaI endonuclease as described for driver DNA to remove A2-originated termini, and purified by passing through a QIAquick PCR Purification Kit. To remove protruding dA at 3′ ends added by AdvanTaq DNA Polymerase, the restricted DNA fragments were treated with Klenow fragment of DNA polymerase I (Fermentas) for 15 min at room temperature in 10 μl of 1× Klenow buffer (Fermentas) and additionally incubated for 15 min in the presence of 125 μM each of dNTPs. Klenow fragment was inactivated by heating at 70°C for 10 min. A 125 ng aliquots of the resulting DNA were ligated to adapters A3A4/a34 (1.7 μM) or A5A6/a56 to form the tracer A and tracer B portions, respectively.

Subtractive hybridization
-------------------------

Tracer A and B samples (16 ng each) were separately mixed with 900 ng of the RsaI digested driver DNA. DNA samples were purified by phenol/chloroform extraction, precipitated with ethanol and dissolved in 2.5 μl of hybridization buffer (0.5 M NaCl, 50 mM HEPES, pH 8.3, 0.2 mM EDTA). A sample of 1800 ng of the driver DNA was also purified, precipitated and dissolved in 5 μl of hybridization buffer.

The tracer A/driver and tracer B/driver samples were denatured at 96°C for 5 min and hybridized separately at 68°C for 3 h to remove the most abundant Alu flanks from each of the two tracer DNA portions. Then 5 μl of driver DNA was denatured at 96°C for 5 min, incubated at 68°C for 5 min, and mixed first with the tracer A/driver and then with the tracer B/driver samples. The resulting mixture was incubated at 68°C overnight and diluted with 100 μl dilution buffer (50 mM NaCl, 5 mM HEPES, pH 8.3, 0.2 mM EDTA). An aliquot of 1 μl of this diluted mixture was pre-incubated at 72°C for 3 min (to fill in the ends of DNA duplexes by AdvanTaq DNA Polymerase) and then PCR amplified with 0.4 μM each of A3 and A5 primers ([Table 1](#tbl1){ref-type="table"}) as follows: 94°C for 20 s, 65°C for 20 s, 72°C for 80 s, 22 cycles. The PCR product was 500-fold diluted and re-amplified with A4 and A6 primers in the second nested PCR round (18 cycles at 94°C for 20 s, 68°C for 20 s, 72°C for 80 s).

Library construction and analysis
---------------------------------

The subtracted PCR product obtained was cloned in *E.coli* DH5α using a TA-cloning system (Promega), and 288 individual clones were arrayed on 96-well microtiter plates. Clones were sequenced by the dye termination method using an ABI Prism 3100-Avant Genetic Analyzer automatic DNA sequencer. Homology searches against GenBank and mapping of the clones were done using the BLAST Web-server at NCBI (<http://www.ncbi.nlm.nih.gov/BLAST>) and the UCSC Human Genome Browser (<http://genome.ucsc.edu/goldenPath/hgTracks.html>).

The primers to verify Alu insertion polymorphism were designed against human genomic sequences surrounding each of Alu Ya5 or Ya8 integration sites. They were used for genomic PCR with the driver and 10 tracer DNA samples. Alu-containing PCR products for the polymorphic insertions represented in GenBank by only Alu-lacking homologs (see below) were cloned and sequenced. For each individual insertion, the PCR product selected for cloning was obtained by amplification of DNA from individuals homozygous for the Alu-containing allele. Otherwise, DNA of heterozygous individuals was amplified, and the longer PCR product was cloned. The clones were then tested for the length of inserts by PCR with standard M13 For/Rev primers, and the Alu-containing inserts were selected for sequencing.

RESULTS
=======

Outline of the method
---------------------

The technique is based on subtractive hybridization of whole-genome fractions of sequences flanking retroelement integration sites in the genomes to be compared. Recently, we successfully applied a similar approach to the identification of HERV-K LTR and L1 insertions distinguishing the human and chimpanzee genomes ([@b7],[@b8],[@b21]). In contrast to other known techniques, the present research is aimed at the identification of RE insertion polymorphisms in the human genome. The technique was adapted to reveal differences between individual human genomes and used in this study to identify Alu Ya5/Ya8 insertion polymorphisms.

A principal distinction of our approach from that developed for interspecies comparison is that an individual human genome was compared to a mixture of ten other individual genomes. This makes it possible to detect even rare polymorphisms. The approach used includes two principal stages (outlined in [Figure 1](#fig1){ref-type="fig"}): A whole-genome selective amplification of the flanks adjacent to Alu elements belonging to the young Ya5 and Ya8 branches in all the 11 genomic DNAs under comparison ([Figure 1A](#fig1){ref-type="fig"}). Ten of the genomes were mixed before the amplification and then used as tracer in the subsequent subtractive hybridization steps. The eleventh genome was amplified separately and then used as driver. For selective amplification, the genomes were first digested with a restriction endonuclease, and the restriction fragments were ligated to a terminal adapter. After this, the fragments with Alu inserts were selectively amplified using a universal primer against a conservative Alu sequence and a primer against the adapter attached.A subtractive hybridization of the amplicons obtained ([Figure 1B](#fig1){ref-type="fig"}). This stage takes into account an unequal abundance of various Alu flanking sequences in the mixture of the amplified DNA fragments. This inequality is due to different frequencies of various Alu containing alleles in the human genome. As a result, the number of copies of particular flanks varies in the range from 0 for Alu-lacking loci to 2*^n^*× (haploid genome equivalents in the initial mixture of the ten genomes), where *n* is the number of PCR cycles used for the amplification of flanks of those Alu inserts present in the given locus of all the genomes used. This variation is supposed to result in the loss of rare and over-representation of frequent polymorphisms in the final complex amplicon. To avoid this effect, we used an equalizing DNA subtraction approach developed by us for cDNA subtraction ([@b22]) and utilized in a subtractive hybridization scheme ([Figure 1B](#fig1){ref-type="fig"}). The approach equalizes the abundance of various flanks in the mixture in the course of subtraction.

A more detailed description of the experiment is presented below.

Driver and tracer amplicons
---------------------------

The tracer amplicon was derived from a mixture of genomic DNAs isolated from 10 human individuals different in their geographic ([Figure 2](#fig2){ref-type="fig"}), ethnic and language origin, as described in Materials and Methods. Mixing several genomes increases the probability of finding polymorphic insertions. The driver amplicon was prepared by selective amplification of the genomic DNA from an Andi male. The DNA of male was chosen to avoid enrichment in non-polymorphic Alu repeats located on Y chromosome.

In order to improve the specificity of selective amplification of Alu containing fragments, we used the 'PCR-suppression' effect (PS-effect) ([@b23]). Briefly, it includes digestion of genomic DNAs ([Figure 1A](#fig1){ref-type="fig"}, stage a) with a frequent cutter restriction enzyme (RsaI in this case) and ligation of the DNA fragments to the A1A2 'pan-handle' forming adapter ([Figure 1A](#fig1){ref-type="fig"}, stage b) followed by two steps of selective PCR. This procedure allows to obtain a specific set of genomic sequences flanking REs of interest (Alu in this case). At this stage, a pair of A1 primer specific to the adapter and T1 target primer corresponding to fragments of the Alu Ya5 and Ya8 consensus sequences was used ([Figure 1A](#fig1){ref-type="fig"}, stage c). These fragments included three diagnostic nucleotides of the Alu Y subfamily and two nucleotides characteristic of the Alu Ya5--Ya8 branch. Presumably, this branch includes about 2500 members in the human genome ([@b4],[@b12]). The fragments obtained in this way contained rather long residual Alu sequences able to cross-hybridize during subtractive hybridization thus affecting the subsequent analysis. To avoid this undesirable effect, the residual sequences were shortened by means of repeated PCR with T2 primer targeted at the utmost 5′ end of Alu repeats and A2 primer against an internal part of A1A2 adapter ([Figure 1A](#fig1){ref-type="fig"}, stage d), the RsaI restriction site being preserved. Both the driver and tracer amplicons were treated with RsaI endonuclease to remove the remainder of A2 adapter ([Figure 1A](#fig1){ref-type="fig"}, stage e).

For the subtraction ([Figure 1B](#fig1){ref-type="fig"}), the tracer amplicon was divided into two portions ([Figure 1A](#fig1){ref-type="fig"}, stage f) each of which was ligated to one of two different 'pan-handle' forming adapters (A3A4 or A5A6, respectively). Then, each of the two samples in separate tubes was mixed with an approximately 50-fold excess of the driver DNA, denatured and incubated under hybridization conditions for 3 h ([Figure 1B](#fig1){ref-type="fig"}, stage a). This stage is an equalizing step during which highly abundant fractions of single-stranded (ss) flanks reassociate at a higher rate than low abundant fractions. As a result, with time the abundances of both the fractions in the ss form become approximately equal. Since the ss fragments also readily reassociate with their driver counterparts, the ss fraction becomes enriched with differential sequences distinguishing driver and tracer DNAs.

After this step, the contents of the two tubes were mixed together and allowed to reassociate ([Figure 1B](#fig1){ref-type="fig"}, stage b) after addition of a new driver portion. Here, only ss and not double-stranded (ds) fragments were capable of reassociation, and only ss fragments from different tubes reassociated with each other to form ds fragments with different termini. All the ds fragments of other origin possessed either two identical termini or one end lacking the adapter. Whereas the fragments with different termini could be further selectively PCR amplified ([Figure 1B](#fig1){ref-type="fig"}, stage d), PCR of the fragments with identical ends was suppressed due to the formation of pan-handle structures between terminal complementary sequences as illustrated in [Figure 1A](#fig1){ref-type="fig"}. Therefore, the resulting amplicon is supposed to be enriched with tracer-specific DNA fragments. We cloned and arrayed the selectively amplified fragments in three 96-well microtiter plates representing a library enriched with polymorphic Alu flanks ([Figure 1B](#fig1){ref-type="fig"}, stage e).

Analysis of the library
-----------------------

Some 125 randomly selected clones of the library were sequenced. All of them contained A4 and A6 oligo sequences at their ends. Five clones lacked a small (20 nt) 5′ part of Alu sequences, while the other 120 clones had this sequence adjacent to either A4 or A6 oligo: 12 of these 120 clone inserts were presented by 2 clones each, 5 by 3 clones, 2 by 4 clones and one sequence by 5 clones. Thus, 120 clones represented 88 individual sequences ([Table 2](#tbl2){ref-type="table"}).

All these 88 sequences were mapped on the human genome using the NCBI human genome databases and the UCSC Genome Browser. Eleven sequences could not be unambiguously mapped due to their small size, presence of low-diverged repetitive elements or chimeras sequences whose parts are homologous to different genomic loci, and/or extended chromosomal duplications. Other 11 sequences corresponded to the loci of young Alu Yb8 (2 sequences), Alu Yc1 (1 sequence) and Alu Ya5 (8 sequences) described earlier ([@b4],[@b14],[@b24],[@b25]). Five of 8 Alu Ya5 insertions (B65, HS2.25, Ya5NBC203, Ya5NBC327 and Ya5DP71) were previously reported to be polymorphic, and three insertions (HS4.21, Ya5NBC46 and Ya5NBC76) were found to be fixed in human populations ([Table 2](#tbl2){ref-type="table"}).

The remaining 66 of 88 sequences containing 5′ portion of Alu corresponded to human genomic loci known to contain Alu insertions or described as not containing any Alu Ya5 or Ya8 insertions. In the contradictory cases, we confirmed the presence of Alu repeats within the identified sites by direct sequencing (see below).

Alu polymorphisms identification
--------------------------------

Sixty-four sequences were analyzed to confirm the Alu insertion polymorphism, and two Alu elements appeared to be integrated into clusters of frequent low-divergent repeats that made impossible reliable selective amplification of the corresponding genomic regions. Sixty-four pairs of PCR primers specific to both 5′ and 3′ flanking sequences of each Alu were designed and used for PCR assay of the 11 human genomic DNAs used as tracer and driver.

Examples of individual locus-specific PCRs are shown in [Figure 3](#fig3){ref-type="fig"}. A total of 41 Alu repeats were identified as polymorphic, while other 18 were found in all the genomes analyzed. It was technically impossible to unambiguously identify the rest five insertions as polymorphic (additional data are available in Supplementary Material).

Frequencies of Alu positive alleles in various loci of the genomes used as tracer components varied from 1/20 to 18/20 (see [Table 3](#tbl3){ref-type="table"} and Supplementary Material for details). As mentioned above ([Table 2](#tbl2){ref-type="table"}), 18 of 41 polymorphic Alu repeats were not found at the expected positions in the draft human genome sequence. To verify whether the PCR length polymorphism is actually due to Alu inserts, the corresponding PCR-products were cloned and sequenced (AY736285--AY736302). For 5 of these 18 polymorphic insertions Alu positive alleles were present in only one genome of the complex tracer, and all of them were heterozygous (see [Table 3](#tbl3){ref-type="table"}). For 2 of these 5 insertions (Ya5-MLS14 and Ya5-MLS20) Alu positive alleles were identified also in other non-tracer human DNA samples, used for optimization of PCR conditions (see Materials and Methods). The remaining three Alu repeats (Ya5-MLS51, Ya5-MLS58 and Ya5-MLS65) can be either polymorphic or represent rare *de novo* insertions.

DISCUSSION
==========

As mentioned above, RE polymorphisms are very useful markers for human population studies and medical genetics. However, most known RE polymorphisms were predicted by *in silico* analysis of human genomic sequences. Although this approach has opened a great opportunity for identification of a great number of polymorphic REs, the published human genome sequences probably lack a significant portion of polymorphic RE insertions \[also suggested in ([@b15])\] because they represent only a few human genomes and do not cover all genetic variations in humans.

We have developed a technique that enables direct experimental isolation of sequences flanking polymorphic RE insertions. The technique allows one to specifically analyze selected subfamilies of certain REs. A high specificity of the technique was confirmed in this study. Here, the technique was used to detect polymorphic insertions of the youngest Alu Ya5 and Ya8 subfamilies\' members. Although Ya5 is an abundant Alu subfamily that includes about 2500 members as compared to several tens of Ya8, there are other young subfamilies practically of similar abundance. For example, Yb8 and Yc1 have quite comparable copy numbers (about 2000 and 400--500, respectively). Nevertheless, only 3 (2.5%) of 120 sequenced Alu-containing clones were found to be flanks of Alu repeats other than the members of the Alu Ya branches. The achieved selectivity of amplification thus seems to be very high and close to 97.5%.

The efficiency of the method with regard to detection of polymorphic insertions seems to be also rather high. Only 21 of 120 sequenced clones (17.5%) were flanks of Alu repeats fixed in the populations, which means about 82.5% 'efficiency' of the technique. According to results of the PCR assay, 78 sequenced clones contain genomic fragments adjacent to Alu repeats that are polymorphic. Some of these 78 clones were redundant and corresponded to 46 independent individual sequences. Five of these sequences were flanks of Alu repeats earlier characterized as insertionally polymorphic (for the numbers see [Table 2](#tbl2){ref-type="table"}). All the remaining 41 identified polymorphic Alu elements belonged to the Alu Ya5 subfamily except one Alu Ya8 element. It is important that 18 (45%) of them originated from Alu containing alleles located in loci known only before our study as Alu-lacking.

The technique permits one to analyze at least 10 different individual DNAs at once (more than the number of completely sequenced genomes available in databases) and identify RE insertions absent from one selected genome and present in at least one of other genomes. The sensitivity of the technique is sufficient to isolate insertions present in only one genome and in a heterozygous state. Since 60--80% of library was represented by polymorphic RE flanks, the use of subtractive hybridization highly increased the efficiency of the subsequent PCR screening. One of major advantages of the technique is the possibility to identify polymorphic Alu repeats not available in human genome databases. The technique allows detecting polymorphisms in wide range of their frequencies in population. Frequencies observed in this study varied in the range of 5--90% ([Table 3](#tbl3){ref-type="table"}).

We have also added some increments to the most recently published ([@b12]) quantitative data on the distribution of polymorphic Alu Ya insertions among human chromosomes ([Table 4](#tbl4){ref-type="table"}). For example, for chromosome 15 we added two new polymorphisms to four reported earlier. Similar increase was found for chromosome 16.

It is difficult to precisely estimate the number of polymorphic insertions absent from one certain genome and present in at least one of other 10 genomes. The total number of Alu Ya5 family members was evaluated to be about 2500, and ∼25% of them are polymorphic in human populations ([@b4],[@b12]). Thus, the total number of polymorphic Alu repeats that can be found in the human genome databases is about 625. Here, we showed that 45% (18 of 41) of the identified polymorphic Alu insertions were lacking from the human genome databases, so the total number of Alu polymorphic insertions can be estimated as high as over 900 in populations of different origin.

The developed technique can be successfully applied to comprehensive searches for polymorphic Alu insertions of other subfamilies, as well as polymorphisms resulted from retroposition of other retroelements. Other possible applications of the technique are identification of specific RE insertion polymorphisms that distinguish human subpopulations or groups and identification of RE polymorphisms presumably associated with hereditary multigene diseases. Moreover, the technique can be easily adapted for using microarrays and to other advanced high throughput formats. Finally, it should be emphasized that the technique can be also successfully used for searching polymorphic RE insertions in genomes with unknown or partially known sequences, e.g. those of various primate species.

SUPPLEMENTARY MATERIAL
======================

Supplementary Material is available at NAR Online.
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###### 

(**A**) Tracer DNA preparation. Double lines denote genomic DNA. R, RsaI restriction sites; open box represents individual Alu Ya5 or Ya8 element. A1A2 (hatched boxes), the first oligonucleotide adapter ligated to the restricted DNA; A1/T1 and A2/T2, primers used in the first and second PCR rounds, respectively. A3A4 (gray boxes) and A5A6 (dark boxes), ligated adapters forming Tracer A and Tracer B, respectively. Note: Driver DNA was prepared from a single sample exactly in the same way as Tracer but omitting stage f. (**B**) Scheme of subtractive hybridization. Wavy lines depict flanking sequences of Alu present in one or more of 10 Tracer genomes and absent from Driver. Straight lines mark flanks of Alu common for Driver and Tracer. Open boxes represent the remainder of Alu Ya5 or Ya8 elements; A3/A5 and A4/A6, primers used in the first and second PCR rounds, respectively. Other designations are as in (A).
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![Geographic origin of populations used for individual DNAs sampling. Territory of Russian Federation is in gray and neighboring countries are white (B, Belarus; U, Uzbekistan; KZ, Kazakhstan). Scale is indicated at the bottom. Dr indicates that Andi genomic DNA sample was used as driver.](gni018f2){#fig2}

![Examples of PCR amplification with three individual polymorphic Alu-containing loci (MLS 19, MLS 50 and MLS 65) in ten tracer (lines t1--t10) and one driver (line Dr) DNA samples. Lines K+ and K− represent positive and negative controls, respectively. M, DNA fragments of a 100 bp ladder length marker (SybEnzime). Gray and white arrows to the left of the electrophoregrams indicate the predicted locations of the Alu containing and Alu-free PCR products, respectively. Scheme of genomic primers location is represented at the bottom.](gni018f3){#fig3}

###### 

Oligonucleotides/primers used for the library construction

  ------ ----------------------------------------------
  A1A2   TGTAGCGTGAAGACGACAGAAAGGGCGTGGTGCGGAGGGCGGT
  A1     TGTAGCGTGAAGACGACAGAA
  A2     AGGGCGTGGTGCGGAGGGCGGT
  a12    ACCGCCCTCC
  A3A4   AGCAGCGAACTCAGTACAACAAGTCGACGCGTGCCCGGGCTGGT
  A3     AGCAGCGAACTCAGTACAACA
  A4     AGTCGACGCGTGCCCGGGCTGGT
  a34    ACCAGCCC
  A5A6   GTAATACGACTCACTGGAGGGCGAGCGTGGTCGCCGCCGAGGTG
  A5     GTAATACGACTCACTGGAGGGC
  A6     GAGCGTGGTCGCCGCCGAGGTG
  a56    CACCTCGGC
  T1     TCACCGTTTTAGCCGGGA
  T2     GTGAGCCACCGCGCCCGG
  ------ ----------------------------------------------

###### 

The numbers of Alu inserts studied and proportions of polymorphic AluYa5 inserts

                                                                   Total                                Alu inserts   
  ---------------------------------------------------------------- ------------------------------------ ------------- ----
  Clones arrayed                                                   288                                                
  Clones sequenced                                                 120                                  78            21
  The number of different Alu flanking sequences                   88                                                 
  Flanking sequences unambiguously mapped on the human genome      77                                                 
  Alu insertions characterized                                                                          46            21
      Previously described                                         8                                    5             3
      Tested by PCR in this work                                   64[a](#tf2-1){ref-type="table-fn"}   41            18
  The number of polymorphic Alu insertions present in databases                                         23            
  The number of polymorphic Alu insertions absent from databases                                        18            

^a^Five of 64 PCR assays resulted in uncertain results (see 'Alu polymorphisms identification' and notes to [Table 3](#tbl3){ref-type="table"}).

###### 

Alu Ya5 genomic location, neighboring genes and polymorphism frequency

  Name        Accession                                  Chromosome   Neighboring genes[b](#tf3-2){ref-type="table-fn"}   Polymorphism frequency[c](#tf3-3){ref-type="table-fn"}   
  ----------- ------------------------------------------ ------------ --------------------------------------------------- -------------------------------------------------------- -------
  Ya5-MLS09   AK056306                                   AL162431     1q25.3                                              2k down *XPR1*                                           7/20
  Ya5-MLS33   AL513546                                                1q21.3                                              No genes                                                 N/A
  Ya5-MLS51   AY736296[a](#tf3-1){ref-type="table-fn"}   AL592148     1q41                                                In AK096526                                              1/20
  Ya5-MLS58   AY736298[a](#tf3-1){ref-type="table-fn"}   AL390117     1p12                                                No genes                                                 1/20
  Ya5-MLS59   AL356501                                   AL365175     1p31.1                                              No genes                                                 7/20
  Ya5-MLS60                                              AL928921     1p36.22                                             No genes                                                 N/A
  Ya5-MLS48   AC073577                                   AC073046     2p13.1                                              In *ACTG2*                                               14/20
  Ya5-MLS26   AY736289[a](#tf3-1){ref-type="table-fn"}   AC099331     3p22.1                                              In *MYRIP*                                               9/20
  Ya5-MLS29   AC011325                                                3q29                                                No genes                                                 13/20
  Ya5-MLS47   AC024248                                                4q26                                                No genes                                                 3/20
  Ya5-MLS57   AY736297[a](#tf3-1){ref-type="table-fn"}   AC010683     4q31.22                                             No genes                                                 2/20
  Ya5-MLS05   AC105756                                   AC087107     4q34.3                                              No genes                                                 5/20
  Ya5-MLS50   AY736295[a](#tf3-1){ref-type="table-fn"}   AC115540     4q35.2                                              No genes                                                 4/20
  Ya5-MLS04   AC114316                                   AC116332     5q14.3                                              No genes                                                 10/20
  Ya5-MLS06   AC020921                                   AC007554     5q14.3                                              No genes                                                 8/20
  Ya5-MLS31   L43392                                                  5q23.3                                              In *RAD50*                                               N/A
  Ya5-MLS44   AY736294[a](#tf3-1){ref-type="table-fn"}   AL365508     6q22.31                                             In c6orf170                                              2/18
  Ya5-MLS19   AC010942                                                6q22.33                                             In *LAMA2*                                               10/20
  Ya5-MLS10   AY736285[a](#tf3-1){ref-type="table-fn"}   AL121969     6p12.2                                              No genes                                                 5/20
  Ya5-MLS14   AY736286[a](#tf3-1){ref-type="table-fn"}   AC019066     7p12.3                                              In *HUS1*, *PKD1L1*                                      1/20
  Ya5-MLS39   AC005377                                                7q34                                                No genes                                                 6/20
  Ya5-MLS23   AP003357                                   AC012482     8q22.1                                              4k up *LAPTM4B*                                          5/20
  Ya5-MLS41   AP005354                                   AC103853     8q23.1                                              In *ZFPM2*                                               14/20
  Ya5-MLS37   AY736292[a](#tf3-1){ref-type="table-fn"}   AC022389     10q23.1                                             4k down *PCDH21*                                         6/20
  Ya5-MLS28   AY736290[a](#tf3-1){ref-type="table-fn"}   AL358033     10p13                                               No genes                                                 2/20
  Ya5-MLS56   AL139818                                                10p15.3                                             No genes                                                 N/A
  Ya5-MLS07   AC025427                                                10q21.1                                             No genes                                                 3/20
  Ya5-MLS35   AL731574                                                10q25.1                                             No genes                                                 18/20
  Ya5-MLS36   AC090832                                                11p11.2                                             In *BHC80*                                               11/16
  Ya5-MLS18   AC080183                                   AC023869     11p14.3                                             In AK127695                                              12/20
  Ya5-MLS45   AC079363                                                12q21.31                                            In *PPFIA2*                                              N/A
  Ya5-MLS34   AY736291[a](#tf3-1){ref-type="table-fn"}   AC009721     12q24                                               In *RPC2*                                                6/18
  Ya5-MLS70   AY736302[a](#tf3-1){ref-type="table-fn"}   AL159153     13q34                                               In *COL4A2*                                              14/20
  Ya5-MLS12   AL138681                                                13q12.3                                             No genes                                                 14/20
  Ya5-MLS46   AL390722                                                13q14.3                                             No genes                                                 14/20
  Ya5-MLS69   AY736301[a](#tf3-1){ref-type="table-fn"}   AL390964     13q21.1                                             No genes                                                 4/20
  Ya5-MLS22   AL161897                                   AE014308     13q33.2                                             No genes                                                 4/20
  Ya5-MLS68   AY736300[a](#tf3-1){ref-type="table-fn"}   AL132990     14q32.13                                            3k up *SERPINA 4*                                        5/20
  Ya5-MLS65   AY736299[a](#tf3-1){ref-type="table-fn"}   AL445883     14q13.1                                             No genes                                                 1/20
  Ya5-MLS11   AC010674                                                15q21.2                                             In *MYO5C*                                               5/20
  Ya5-MLS21   AC021958                                   AC026583     15q23                                               No genes                                                 9/20
  Ya5-MLS63   AC130456                                   AC003108     16p12.3                                             In *TMC5*                                                3/18
  Ya8-MLS32   AC139236                                   AC140504     16p13.1                                             No genes                                                 3/20
  Ya5-MLS16   AY736287[a](#tf3-1){ref-type="table-fn"}   AC108483     16q23.2                                             No genes                                                 3/16
  Ya5-MLS30   AC016586                                                19p13.3                                             8k up *EEF2*                                             16/18
  Ya5-MLS20   AY736288[a](#tf3-1){ref-type="table-fn"}   AL135935     20p12.2                                             In *PAK7*                                                1/20
  Ya5-MLS66   AC023275                                                1q31.1                                              In *FIBL-6*                                              FP
  Ya5-MLS13   AL590082                                                1p21.1                                              No genes                                                 FP
  Ya5-MLS62   AC079300                                                2p16.3                                              No genes                                                 FP
  Ya5-MLS49   AC108068                                                2q32.3                                              No genes                                                 FP
  Ya5-MLS52   AC016903                                                2q33.3                                              No genes                                                 FP
  Ya5-MLS24   AC019130                                                2q37.1                                              In MGC42174                                              FP
  Ya5-MLS61   AC099339                                                4q31.3                                              In *ARFIP1*                                              FP
  Ya5-MLS55   AC094098                                                5q33.2                                              No genes                                                 FP
  Ya5-MLS25   AL139093                                                6p22.3                                              No genes                                                 FP
  Ya5-MLS38   AC006006                                                7q34                                                In *BRAF*                                                FP
  Ya5-MLS15   AL355592                                                9q33.1                                              No genes                                                 FP
  Ya5-MLS53   AC069540                                                10q23.1                                             No genes                                                 FP
  Ya5-MLS42   AC022878                                                11p15.3                                             No genes                                                 FP
  Ya5-MLS43   AP001782                                                11q24.1                                             No genes                                                 FP
  Ya5-MLS01   AC023795                                                12q12                                               In *CPNE8*                                               FP
  Ya5-MLS27   AC078860                                                12q21.1                                             2k down *GPR49*                                          FP
  Ya5-MLS67   AC007432                                                17q24.3                                             No genes                                                 FP
  Ya5-MLS54   AL031657                                                20q11.23                                            4k up *PPP1R16B*                                         FP

^a^For Alu repeats that were sequenced in this work for the first time accession numbers obtained in this work are given.

^b^Neighboring genes were detected by Human Genome Browser under RefSeq Genes. Up, Alu is *N* kb upstream gene; down, Alu is *N* kb downstream gene; in, Alu is into intron of gene; no genes, no neighboring genes were detected within 10 kb of Alu.

^c^For polymorphic Alu repeats fraction of Alu-positive haplotypes to the total haplotypes tested for tracer DNA. Driver DNA for polymorphic insertions is always Alu negative. FP (fixed present), all the DNA samples tested were Alu-positive; N/A, PCR products were not detected for driver DNA sample, or the samples were Alu negative, or no specific PCR products detected for driver and tracer DNAs.

###### 

Chromosomal distribution of polymorphic Alu Ya5 and Ya8 repeats found in this work compared to the distribution of other polymorphic REs detected by *in silico* approach

  Chromosome   Polymorphic (other works)[a](#tf4-1){ref-type="table-fn"}   Polymorphic (this work)[b](#tf4-2){ref-type="table-fn"}   Total polymorphic
  ------------ ----------------------------------------------------------- --------------------------------------------------------- -------------------
  1            24                                                          4                                                         28
  2            29                                                          1(1)                                                      29
  3            18                                                          2                                                         20
  4            20                                                          4(1)                                                      23
  5            18                                                          2(1)                                                      19
  6            27                                                          3(1)                                                      29
  7            37                                                          2                                                         39
  8            10                                                          2                                                         12
  9            6                                                           0                                                         6
  10           13                                                          4(1)                                                      16
  11           12                                                          2                                                         14
  12           12                                                          1                                                         13
  13           18                                                          5(2)                                                      21
  14           17                                                          2                                                         19
  15           4                                                           2                                                         6
  16           7                                                           3(1)                                                      9
  17           10                                                          0                                                         10
  18           7                                                           0                                                         7
  19           5                                                           1                                                         6
  20           12                                                          1                                                         13
  21           4                                                           0                                                         4
  22           3                                                           0                                                         3
  Total        313                                                         41                                                        346

^a^Cited from ([@b12]).

^b^Number of polymorphic insertions identical to those described by Mark Batzers group \[Otieno *et al*. ([@b12])\] recently are given in brackets.

[^1]: DDBJ/EMBL/GenBank accession nos [AY736285](AY736285)--[AY736302](AY736302)
